APE1/Ref-1 as a Therapeutic Target for Inflammatory Bowel Disease

APE1/Ref-1 as a Therapeutic Target for Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is characterized by chronic relapsing inflammation of the gastrointestinal tract. The prevalence of IBD is increasing with approximately 4.9 million cases reported worldwide. Current therapies are limited due to the severity of side effects and long-term toxicity, th...

Full description

Bibliographic Details
Main Authors: Lauren Sahakian, Ainsley M. Robinson, Linda Sahakian, Rhian Stavely, Mark R. Kelley, Kulmira Nurgali
Format: Article
Language:English
Published: MDPI AG 2023-10-01
Series:Biomolecules
Subjects:
apurinic/apyrimidinic endonuclease 1/reduction-oxidation factor 1 (APE1/Ref-1)
redox signaling
inflammatory bowel disease (IBD)
inflammation
oxidative stress
Online Access:https://www.mdpi.com/2218-273X/13/11/1569

Internet

https://www.mdpi.com/2218-273X/13/11/1569

Similar Items